EGFR and non-small cell lung carcinoma: In the past decade, the advancement of molecular targeted therapies has greatly improved the survival of patients with advanced NSCLC, in which EGFR-tyrosine kinase inhibitors (EGFR-TKIs) was a tremendous success.